Literature DB >> 30353651

A reproducible strategy for analysis of minimal residual disease measured by Standardized multiparametric flow cytometry in b acute lymphoblastic leukemia.

Hector Sarmiento Palao1, Fabián Tarín1, Fernanda Martirena2, Eva Barragán3, Esperanza Such3, Amparo Sempere3, Maria Tasso4, Pablo Manresa1, Francisco López1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30353651     DOI： 10.1002/cyto.b.21720

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN： 1552-4949            Impact factor:   3.058


× No keyword cloud information.
  3 in total

1.  Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.

Authors:  Nupur Das; Ritu Gupta; Sanjeev Kumar Gupta; Sameer Bakhshi; Rachna Seth; Chandan Kumar; Sandeep Rai; Saroj Singh; Vijay Kumar Prajapati; Ajay Gogia; Ranjit Kumar Sahoo; Atul Sharma; Lalit Kumar
Journal:  Ann Hematol       Date:  2021-07-08       Impact factor: 3.673

Review 2.  Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation.

Authors:  In-Suk Kim
Journal:  Blood Res       Date:  2020-07-31

3.  The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease.

Authors:  Hongyan Liao; Qin Zheng; Yongmei Jin; Tashi Chozom; Ying Zhu; Li Liu; Nenggang Jiang
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.